Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00405353 · ClinicalTrials.gov registry record · Phase 1
Testosterone Treatment for Multiple Sclerosis
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT00405353: Completed Phase 1 study, sponsored by University of California, Los Angeles.
NCT00405353 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00405353, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.
Primary Outcome
as assessed by Voxel-Based Morphometry
Interventions
- DRUG Androgel 10 grams of gel containing 100 mg of testosterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2002-04 |
| Est. Completion | 2007-03 |
| Phase | Phase 1 |
What the finished NCT00405353 record still lists
NCT00405353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Androgel 10 grams of gel containing 100 mg of testosterone is the first listed.
NCT00405353 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00405353 about?
NCT00405353 is a clinical study titled "Testosterone Treatment for Multiple Sclerosis". Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.
What is the current status of trial NCT00405353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2002-04. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00405353?
The interventions under investigation include: Androgel 10 grams of gel containing 100 mg of testosterone (DRUG).
Who is sponsoring clinical trial NCT00405353?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00405353's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia